ResultsIQ

ResultsIQ › Latest results › Mankind Pharma Limited

Mankind Pharma Limited Q1 FY26 earnings call summary

NSE: MANKIND · BSE: 543904

Earnings call of 1 Aug 2025, summarised by AI from the filing.

₹3,570 cr (Q1 FY25: ₹2,868 cr, +24.5%), driven by base business growth and BSV consolidation.

Key takeaways

  1. Revenue ₹3,570 cr (Q1 FY25: ₹2,868 cr, +24.5%), driven by base business growth and BSV consolidation.
  2. Guidance EBITDA margin maintained at 25% to 26% for FY26; gross margin upward of 70%.
  3. Change PAT decreased 17.4% year-on-year to ₹445 cr on higher finance and depreciation costs from BSV.
  4. Risk Gross margin declined 130 bps to 70.5% due to unfavorable sales mix and inventory-related accruals.

Original filing on BSE

Mankind Pharma Limited Q1 FY27 results

As filed: Revenue ₹4,031 cr (+13% year on year), EBITDA ₹1,056 cr (+25% year on year), PAT ₹574 cr (+29% year on year), EBITDA margin 26.2% (+248 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹3,443 cr (+12% year on year), EBITDA ₹930 cr (+36% year on year), PAT ₹559 cr (+32% year on year), EBITDA margin 27.0% (+479 bps). Score 63 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was above it. EBITDA margin rose 479 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹364 cr on a year ago, against ₹638 cr the year before. Share price after the results: −3.5% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹3,567 cr (+10% year on year), EBITDA ₹919 cr (+11% year on year), PAT ₹414 cr (+24% year on year), EBITDA margin 25.8% (+8 bps). Score 42 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit before exceptional items growth was above it. EBITDA margin was flat year on year. Revenue fell 4% from last quarter. Revenue rose ₹337 cr on a year ago, against ₹623 cr the year before. Share price after the results: +3.0% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹3,697 cr (+20% year on year), EBITDA ₹922 cr (+8% year on year), PAT ₹520 cr (−21% year on year), EBITDA margin 24.9% (−272 bps). Score 44 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 272 bps year on year. Revenue rose ₹620 cr on a year ago, more than the ₹369 cr it added the year before. Share price after the results: −4.5% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹3,570 cr (+23% year on year), EBITDA ₹847 cr (+24% year on year), PAT ₹445 cr (−18% year on year), EBITDA margin 23.7% (+15 bps). Score 56 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 15 bps year on year. Revenue rose ₹677 cr on a year ago, more than the ₹314 cr it added the year before. Share price after the results: −3.7% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹3,079 cr (+26% year on year), EBITDA ₹684 cr (+16% year on year), PAT ₹425 cr (−11% year on year), EBITDA margin 22.2% (−200 bps). Score 40 of 100, Below trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 200 bps year on year. Other income 49% of PBT. Revenue fell 5% from last quarter. Share price after the results: −9.6% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹3,230 cr (+24% year on year), EBITDA ₹830 cr (+37% year on year), PAT ₹385 cr (−16% year on year), EBITDA margin 25.7% (+241 bps). Score 64 of 100, In line with trend. EBITDA margin rose 241 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 42% from last quarter.
  • Q2 FY25: Revenue ₹3,077 cr (+14% year on year), EBITDA ₹851 cr (+25% year on year), PAT ₹659 cr (+29% year on year), EBITDA margin 27.7% (+244 bps). Score 69 of 100, Above trend. EBITDA margin rose 244 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Mankind Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.